SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 3, 2004
Eyetech Pharmaceuticals, Inc.
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-50516 13-4104684
- --------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Numbers) Identification No.)
3 Times Square, 12th Floor
New York, NY 10036
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (212) 824-3100
500 Seventh Avenue, 18th Floor
New York, NY 10018
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
ITEM 5. OTHER EVENTS
On May 3, 2004, Eyetech Pharmaceuticals, Inc. announced information
regarding its Phase 2 clinical trials for the use of Macugen(TM) in the
treatment of diabetic macular edema, known as DME, which is a complication of
diabetic retinopathy. The full text of the press release issued in connection
with the announcement is furnished as Exhibit 99.1 to this Current Report on
Form 8-K.
ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On May 3, 2004, Eyetech Pharmaceuticals, Inc. announced its financial
results for the quarter ended March 31, 2004. The full text of the press release
issued in connection with the announcement is furnished as Exhibit 99.2 to this
Current Report on Form 8-K.
The information in this Item 12 of Form 8-K (including Exhibit 99.2) shall
not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act
of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: May 3, 2004 EYETECH PHARMACEUTICALS, INC.
By: /s/ Glenn P. Sblendorio
-----------------------------------
Name: Glenn P. Sblendorio
Title: Senior Vice President, Finance and
Chief Financial Officer
EXHIBIT INDEX
Exhibit No. Description
- ----------- -----------
99.1 Press release dated May 3, 2004 announcing information
regarding Phase 2 clinical trials results for the use of
Macugen in the treatment of diabetic macular edema
99.2 Press release dated May 3, 2004 announcing financial
results for the quarter ended March 31, 2004